Free tool
FAERS Monitor: Jubbonti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761362 or its brand name (Jubbonti, Denosumab-Bbdz). Reports on generic versions are filed under their own applications.
Reports
16,950
Serious
16,209
96% of reports
Hospitalization
6,904
Death reported
2,031
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- osteonecrosis of jaw1,555
- diarrhoea1,184
- fatigue1,152
- nausea1,101
- malignant neoplasm progression1,072
- neutropenia981
- metastases to bone858
- off label use847
- anaemia759
- vomiting627
- dyspnoea611
- hypocalcaemia611
- decreased appetite608
- death596
- arthralgia566
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 67 |
| 2011 | 136 |
| 2012 | 214 |
| 2013 | 358 |
| 2014 | 474 |
| 2015 | 662 |
| 2016 | 748 |
| 2017 | 636 |
| 2018 | 956 |
| 2019 | 1,013 |
| 2020 | 1,063 |
| 2021 | 1,495 |
| 2022 | 1,772 |
| 2023 | 1,782 |
| 2024 | 1,733 |
| 2025 | 1,823 |
| 2026 | 2,015 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,209 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| osteonecrosis of jawSignal | 1,555 | 83.1 | 79.1 | 118,318 |
| metastases to boneSignal | 858 | 68.4 | 63.9 | 53,974 |
| hypocalcaemiaSignal | 611 | 41.4 | 38.2 | 23,268 |
| malignant neoplasm progressionSignal | 1,072 | 13.1 | 12.4 | 11,919 |
| neutropeniaSignal | 981 | 9.0 | 8.5 | 6,973 |
| anaemiaSignal | 759 | 5.0 | 4.6 | 2,404 |
| decreased appetiteSignal | 608 | 3.3 | 3.0 | 955 |
| diarrhoeaSignal | 1,184 | 2.3 | 2.2 | 873 |
| fatigue | 1,152 | 1.8 | 1.7 | 455 |
| nausea | 1,101 | 1.7 | 1.6 | 349 |
| arthralgia | 566 | 1.7 | 1.6 | 162 |
| vomiting | 627 | 1.7 | 1.5 | 166 |
| dyspnoea | 611 | 1.3 | 1.2 | 54 |
| off label use | 847 | 1.2 | 1.1 | 29 |
| death | 596 | 0.9 | 0.8 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.